Therapeutic cancer vaccines direct a person’s own immune cells against tumors. What if we could use that approach to prime CAR-T cells so that they could work against solid tumors? A platform to do just that has been licensed to Elicio Therapeutics, which nabbed $30 million to help fund its first human studies.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,